SHP2 is usually overexpressed in NSCLC; however, its association with the progression and development of the disease as well as the molecular mechanism by which SHP2 contributes to tumour cell growth remain largely unclear. This evidence concerns the gene PTPN11 and non-small cell lung carcinoma.